Abstract
Background
Sentinel lymph node biopsy (SLNB) is recommended for intermediate thickness melanoma, but for thick melanoma, guidelines are less definitive about the use of SLNB in this population. We present a study on thick melanoma evaluating for prognostic factors.
Patients and Methods
The Sentinel Lymph Node Working Group database was queried for thick (> 4 mm) melanoma cases that had a SLNB from 1993 to 2018. Clinicopathologic characteristics were correlated with SLN status and melanoma-specific survival (MSS).
Results
There were 1235 patients. Median follow-up was 28 months. Median thickness was 5.9 mm, with 956, 175, and 104 cases presenting thickness > 4–8, > 8–12, and > 12 mm, respectively. SLN metastases were seen in 439 of 1235 (35.5%) cases and in 33.9%, 40.6%, and 42.3% of melanomas > 4–8, > 8–12, and > 12 mm, respectively. In each thickness group, MSS was significantly worse for SLN-positive compared with SLN-negative cases (all P < 0.005). Multivariable analysis showed that SLN metastasis, male gender, increasing thickness, lymphovascular invasion, and microsatellitosis significantly predicted worse MSS for melanomas > 4–8 mm, with SLN metastasis showing the greatest risk (HR 2.17, 95% CI 1.64–2.87, P < 0.0001). For melanomas > 8 mm, only SLN metastasis significantly predicted MSS (> 8–12 mm: HR 3.93, 95% CI 2.00–7.73, P < 0.0001; > 12 mm: HR 3.58, 95% CI 1.56–8.22, p < 0.0027).
Conclusions
Thick melanoma patients with SLN metastasis have significantly worse MSS compared with SLN-negative patients, even in the thickest cases, and SLN status is the most powerful and/or only predictor of MSS. Given these results, SLNB shows important prognostic value in this population and is indicated for clinically localized thick melanoma.
Similar content being viewed by others
References
Coit DG, Thompson JA, Albertini MR, et al. Cutaneous Melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(4):367–402.
Gershenwald JE, Scoyler RA, Hess KR, Thompson JF, Long GV, Ross MI, et al. Melanoma of the skin. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare DA, Madera M, Gress DM, Meyer LR, editors. AJCC cancer staging manual. Basel: Springer; 2017. p. 563–85.
Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(4):399–413.
Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.
Bello DM, Han G, Jackson L, et al. The prognostic significance of sentinel lymph node status for patients with thick melanoma. Ann Surg Oncol. 2016;23(Suppl 5):938–45.
Kachare SD, Singla P, Vohra NA, Zervos EE, Wong JH, Fitzgerald TL. Sentinel lymph node biopsy is prognostic but not therapeutic for thick melanoma. Surgery. 2015;158(3):662–8.
Rughani MG, Swan MC, Adams TS, et al. Sentinel node status predicts survival in thick melanomas: the Oxford perspective. Eur J Surg Oncol. 2012;38(10):936–42.
Murtha TD, Han G, Han D. Predictors for use of sentinel node biopsy and the association with improved survival in melanoma patients who have nodal staging. Ann Surg Oncol. 2018;25(4):903–11.
Yamamoto M, Fisher KJ, Wong JY, et al. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer. 15 2015;121(10):1628–36.
Ribero S, Osella-Abate S, Sanlorenzo M, et al. Sentinel lymph node biopsy in thick-melanoma patients (N = 350): what is its prognostic role? Ann Surg Oncol. 2015;22(6):1967–73.
Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–9.
Ross MI, Reintgen D, Balch CM. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol. 1993;9(3):219–23.
White RL, Jr., Ayers GD, Stell VH, et al. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011;18(13):3593–600.
Fujisawa Y, Otsuka F, Japanese Melanoma Study G. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (> 4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients. Melanoma Res. 2012;22(5):362–367.
Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000;7(2):160–5.
Scoggins CR, Bowen AL, Martin RC, 2nd, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg. 2010;145(7):622–7.
Gajdos C, Griffith KA, Wong SL, et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer. 15 2009;115(24):5752–60.
Mozzillo N, Pennacchioli E, Gandini S, et al. Sentinel node biopsy in thin and thick melanoma. Ann Surg Oncol. 2013;20(8):2780–6.
White I, Fortino J, Curti B, Vetto J. Clinical impact of sentinel lymph node biopsy in patients with thick (> 4 mm) melanomas. Am J Surg. 2014;207(5):702–7.
Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9(7):637–45.
Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–17.
Feigelson HS, Powers JD, Kumar M, Carroll NM, Pathy A, Ritzwoller DP. Melanoma incidence, recurrence, and mortality in an integrated healthcare system: a retrospective cohort study. Cancer Med. 2019;8(9):4508–16.
Portinari M, Baldini G, Guidoboni M, et al. The long-term prognostic impact of sentinel lymph node biopsy in patients with primary cutaneous melanoma: a prospective study with 10-year follow-up. Ann Surg Treat Res. 2018;95(5):286–96.
Namikawa K, Aung PP, Gershenwald JE, Milton DR, Prieto VG. Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. Cancer Med. 2018;7(3):583–93.
Bartlett EK, Gupta M, Datta J, et al. Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2014;21(3):1016–23.
Karakousis GC, Gimotty PA, Leong SP, et al. Microsatellitosis in patients with melanoma. Ann Surg Oncol. 2019;26(1):33–41.
Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11(3):247–58.
Balch CM, Thompson JF, Gershenwald JE, et al. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014;21(4):1075–81.
Jaukovic L, Sijan G, Rajovic M, et al. Lymphoscintigraphy and sentinel lymph node biopsy, in cutaneous melanoma staging and treatment decisions. Hell J Nucl Med. 2015;18(2):146–51.
Bello DM, Chou JF, Panageas KS, et al. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol. 2013;20(11):3618–25.
Pavri SN, Han G, Khan S, Han D. Does sentinel lymph node status have prognostic significance in patients with acral lentiginous melanoma? J Surg Oncol. 2019;119(8):1060–9.
Basurto-Lozada P, Molina-Aguilar C, Castañeda-Garcia C, et al. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. Pigment Cell Melanoma Res. 2020. https://doi.org/10.1111/pcmr.12885.
Goydos JS, Shoen SL. Acral lentiginous melanoma. Cancer Treat Res. 2016;167:321–9.
Cadili A, Dabbs K. Predictors of sentinel lymph node metastasis in melanoma. Can J Surg. 2010;53(1):32–6.
Busam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol. Mar 2005;12(2):92–102.
Nicolson NG, Han D. Desmoplastic melanoma. J Surg Oncol. 2019;119(2):208–215.
Han D, Zager JS, Yu D, et al. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? Ann Surg Oncol. 2013;20(7):2345–2351.
Thelmo MC, Sagebiel RW, Treseler PA, et al. Evaluation of sentinel lymph node status in spindle cell melanomas. J Am Acad Dermatol. 2001;44(3):451–455.
Eroglu Z, Zaretsky JM, Hu-Lieskovan S, et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018;553(7688):347–350.
Funding
This work was not supported by any funding source.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Dr. Sondak (V.K.S.) reports being a paid consultant to Array, BMS, Merck, Pfizer, Polynoma, Regeneron, and Replimune. Dr. Zager (J.S.Z.) reports having research funding from Amgen, Castle Biosciences, Delcath Systems, Novartis, Provectus, and Philogen, being on the medical advisory board for Delcath Systems, the speakers’ bureau for Sun Pharma, Array Biopharma/Pfizer, and Castle Biosciences, in addition to consulting for Merck, Sanofi/Regeneron, Amgen, and Sun Pharma. All other authors report no conflicts.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Han, D., Han, G., Duque, M.T. et al. Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas. Ann Surg Oncol 28, 1007–1016 (2021). https://doi.org/10.1245/s10434-020-08706-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08706-0